**Name of journal: World Journal of Gastroenterology**

**ESPS Manuscript NO: 6758**

**Columns: TOPIC HIGHLIGHT**

WJG 20th Anniversary Special Issues (8): Gastric cancer

**Characteristics of gastric cancer in Asia**

Rahman R *et al*. Gastric cancer in Asia

Rubayat Rahman, Akwi W Asombang, Jamal A Ibdah

**Rubayat Rahman, Akwi W Asombang, Jamal A Ibdah,**Division of Gastroenterology and Hepatology, University of Missouri School of Medicine, One Hospital Drive, Columbia, MO 65212, United States

**Author contributions:** Rahman R wrote the manuscript; Asombang AW was involved in reviewing the literature and manuscript; Ibdah JA provided overall intellectual input into the design and edited the manuscript.

**Correspondence to: Jamal A Ibdah, MD, PhD, Professor, Director,** Division of Gastroenterology and Hepatology, University of Missouri School of Medicine, One Hospital Drive, CE 405, Columbia, MO 65212, United States. ibdahj@health.missouri.edu

**Telephone:** +1-573-8827349 **Fax:** +1-573-8844595

**Received:** October 28, 2013 **Revised:** January 26, 2014

**Accepted:** February 17, 2014

**Published online:**

**Abstract**

Gastric cancer (GC) is the fourth most common cancer in the world with more than 70% of cases occur in the developing world. More than 50% of cases occur in Eastern Asia. GC is the second leading cause of cancer death in both sexes worldwide. In Asia, GC is the third most common cancer after breast and lung and is the second most cause of cancer death after lung cancer. Although the incidence and mortality rates are slowly declining in many countries of Asia, GC still remains a significant public health problem. The incidence and mortality varies according to the geographic area in Asia. These variations are closely related to the prevalence of GC risk factors; especially *Helicobacter pylori*(*H. pylori*) and its molecular virulent characteristics. The gradual and consistent improvements in socioeconomic conditions in Asia have lowered the *H. pylori* seroprevalence rates leading to a reduction in the GC incidence. However, GC remains a significant public health and an economic burden in Asia. There has been no recent systemic review of GC incidence, mortality, and *H. pylori* molecular epidemiology in Asia. The aim of this report is to review the GC incidence, mortality, and linkage to *H. pylori* in Asia.

© 2014 Baishideng Publishing Group Co., Limited. All rights reserved.

**Key words:** Gastric cancer; Asia; Epidemiology; Gastric cancer incidence; Gastric cancer mortality

**Core tip:** Gastric cancer (GC) is the third most common cancer and the second most common cause of cancer death in Asia. Highest incidence rates are observed in Eastern Asia and varies in other parts of Asia. Mortality rates are slowly declining but remain a significant public health problem. The seroprevalence of *Helicobacter pylori* is very closely related to the incidence of GC in Asia. In contrast to Western world, management of GC is focused on prevention and early detection in Eastern Asia.

Rahman R, Asombang AW, Ibdah JA. Characteristics of gastric cancer in Asia.

**Available from: URL:**

**DOI:**

**INTRODUCTION**

Gastric cancer (GC) is a heterogeneous, multi factorial disease. It endangers human physical and psycho-social wellbeing, causing a significant public health and economic burden both in the developed and developing countries[1,2]. According to International Agency for Research on Cancer (IARC), the global and regional burden of GC is enormous[3]. The incidence and mortality vary widely according to geographic areas, socio-cultural and economic entities. GLOBOCAN 2008 data revealed that about one million new cases of GC were estimated to have diagnosed in 2008, making it the fourth most common malignancy in the world, after lung, breast, and colorectal cancers. More than 70% of GC cases occur in developing countries with half the world’s total cases occurring in Eastern Asia[1,2]. Overall, GC incidence and mortality have fallen dramatically over the past 70 years. Despite its recent decline, GC is the second leading cause of cancer death in both sexes worldwide. The highest mortality rates occur in Eastern Asia while the lowest occur in Northern America. In Asia, GC is the third most common cancer after breast and lung. But is the second most cause of cancer death in Asia after lung cancer[2,3]. Although the incidence and mortality rates of GC are slowly declining in Asia, it still remains a significant health problem. Asia is the world’s largest and most populous continent. With approximately 4.3 billion people, it accounts for 60% of the world’s current human population. Asia’s growth rate is very high for the modern era and has quadrupled during the last 100 years. It is estimated that Asia’s growth rate will remain high [3,4]. There has been no recent systemic review of GC incidence, mortality and *H. pylori* molecular epidemiology in Asia.

**CURRENT EPIDEMIOLOGY OF GC**

More than 727000 cases of GC were diagnosed in Asia in 2008, accounting for 11.9% of all the cancers diagnosed. It is the third most common cancer in Asia after breast and lung cancer[3]. Table 1 shows that the age-standardized rate (ASR) of incidence is highest in Asia (18.5%) compared to other continents. The ASR of mortality is also highest (13.4%) and it is second only to lung cancer (19.15) in Asia. It is the third most prevalent cancer in Asia after breast and colorectal cancers[3]. The incidence and mortality rates of GC are also the highest in both males and females in Asia compared to other continents (Tables 2 and 3) [3,5].

The incidence and mortality rates are also higher in Eastern Asia compared to other regions in Asia. This region includes China, Japan and South Korea, the three countries with the highest GC incidence and mortality rates, while the lowest rates occur in South-Central Asia[1,3,5,6] The age adjusted GC incidence, mortality, and prevalence rates in the various regions in Asia are summarized in Table 4. In all the four parts of Asia, the rates are lower in females than males as shown in Tables 5 and 6[1–5].

**CURRENT INCIDENCE TREND OF GC IN ASIA**

More than half of the world’s population live in Asia[2] China, Japan and South Korea have reported the highest GC incidence rate both in males and females in the world. More than half of the total cases of GC are diagnosed in East Asia each year[1,2,5,6]. Overall, the incidence rate trend of GC in Asia is declining in the last two decades. Although the incidence rate of GC remains somewhat unchanged in some countries of Asia, the overall incidence rate of GC in East Asia is declining[7]. In China, the incidence rate of GC in males declined from 41.9 per 100000 in 2000 to 37.1 per 100000 in 2005[8,9]. While from 2000 to 2005, GC incidence rate decreased from 19.5 to 17.4 per 100000, respectively in females[1,8,9]. In Japan, the incidence rate of GC declined from about 80 to 60 per 100000 from 1980 to 2000. In 2008, the incidence rate of GC in Japan was 31.1 per 100000 both in males and females[5,10,11]. In South Korea, the incidence rate of GC also declined to 65.6 per 100000 in males and 25.8 per 100000 in females[2,6,12]. Many countries of South-East Asia (Singapore, Thailand, and Malaysia) have also observed a slow decline of GC incidence rate over the last few decades[2,3].

The overall incidence rate of GC in South-Central Asia is low in comparison to the other parts of Asia. The incidence of GC in India (3.8 per 100000) is overall less than the worldwide incidence. The age-adjusted rate of GC among urban registries in India is 3.0–13.2 per 100000[2,3]. Overall, the incidence rate of GC in India is decreasing. However, this declining trend has not been seen in certain parts of India. Among the major population-based cancer registries in India, only Mumbai and Chennai have reported a decline in incidence. The incidence rate of GC in other parts of South-Central Asia like Pakistan, Bangladesh and Sri Lanka is also decreasing slowly[2–4,13,14].

Western Asia is the land of multiple ethnic groups, principally from three main backgrounds: Semitic (Arabs and Jews), Indo-European (Persians and Kurdish) and Turkic (Turkish and Turkmens). Its geographic location, which has been under continuous influences from Asia, Europe and Africa, has variable incidence rates of GC. The GC rate differs in this region from very high in Iran (26.1 per 100000)) to low in Israel (12.5 per 100000)[3,15,16]. GC occurs nearly 7 times more frequently in Iran than in Iraq[17]. In Jordan, the overall incidence rate is 4.8 per 100000 (males 5.6 and females 4.1)[3,15,16]. The incidence rate of GC and its trend remains stable or improving slowly in most of the countries in Western Asia[3,15–17].

**GC MORTALITY IN ASIA**

The overall GC mortality rate and its variations according to geographic areas closely follow the distribution of the GC incidence rate in the world as well as in Asia. In Asia, the mortality rate is higher in males than females[3]. Similar to the incidence rate, GC mortality rate is the highest in Eastern Asia (Table 4)[3]. Mortality rates also vary in different countries in Asia (Table 7). China has the highest mortality rate from GC (30.1 per 100000) followed by Japan (20.5 per 100000) and South Korea (13.8 per 100000). The mortality rate is moderate to low in South-Eastern Asia (Malaysia 8.5 per 100000), while relatively low in South-Central Asia (India 4.6 and Bangladesh 5.7 per 100000). The mortality rates vary in Western Asia (Iran 19.9, Israel 6.7, Jordan 5.2 and Iraq 3.7 per 100000)[1,3,5,6,8,15].

**CURRENT MORTALITY TREND OF GC IN ASIA**

In the new millennium, there have been some distinct and progressive changes in the pattern of gastrointestinal cancer – especially in GC in Asia. Despite all the recent changes in screening, diagnosis, treatment and surveillance, GC still remains the second most common cause of cancer mortality in Asia[3]. The mortality rate of GC remains statistically unchanged in some countries of Asia, however, a significant decline in the mortality rate of GC in Eastern Asia led to an overall decline in the mortality rate in Asia[7]. In China, the highest mortality rate was observed in rural areas, especially in Gansu, Henan, Hebei, Shanxi and Shaanxi Provinces in the middle-western part of China[8,9]. Although there was a slight increase from the 1970s to early 1990s, a significant decline in GC mortality was noticed in almost the entire population during the last decade in China. Between 2000 and 2005, Mortality from GC declined in males, while the number slightly increased in females, despite the significant declining trend in mortality rates among all age groups in China. In 2008, the mortality rates of GC in China were 30.1 in males and 14.6 in females per 100000[1,7,8].

There has been a significant change in the mortality trend of GC in Japan. This country has had a significant decline in the mortality rate of GC from 1980 to 2010. In 2008, the overall mortality rate was 14.7 per 100000 (20.5 and 12.6 per 100000 in males and females, respectively) [2,3,11]. Similar decline was also observed in South Korea [2,3,12]. The mortality rate also declined in most of the countries in Eastern and South-Eastern Asia [2,3,7,18].

There was a decline in the mortality rates of GC in urban areas of India (overall 3.6, male 4.6, and female 2.7 per 100000 in 2008). But in many rural areas, the mortality rate still remains high and unchanged. The mortality rates in other countries in South-Central Asia remain low and unchanged. Iran has the highest mortality rate of GC in South-Central and Western Asia. The overall mortality rate is 14.1 per 100000 (male 19.9 and female 8.2) and is slowly declining. The mortality rate remains low and improving slowly in Jordan (overall 4.5, male 5.2 and female 3.8 per 100000) and Israel (overall 4.7, male 6.7 and female 3.0 per 100000) [3,13–15].

**EPIDEMIOLOGY OF *HELICOBACTER PYLORI* INFECTION IN ASIA**

It is well postulated that the seroprevalence of *Helicobacter pylori*(*H. pylori*) is very closely related to the incidence of GC. There is a difference in the seroprevalence of *H. pylori* infection between countries and within specific regions and communities of individual countries, not only in Asia but also in other countries of the world. In tandem with the socioeconomic development in many countries, a temporal decrease in the seroprevalence rate has been reported [2].

The seroprevalence rates of *H. pylori* infection in under-developed or developing countries are higher than in developed countries. The highest seroprevalence rate is reported in Bangladesh (92%) followed by Kuwait (84%) and India (79%) [2,19,20]. On the other hand, the seroprevalence rates in developed countries are reported to be lower. Among East Asian countries, the overall seroprevalence rate is 58.07% in China, 39.3% in Japan, 59.6% in South Korea and 54.5% in Taiwan [21–24]. Among Southeast Asian countries, the reported seroprevalence rate was 35.9% in Malaysia, 31% in Singapore, 75% in Vietnam and 57% in Thailand [2,7,18,25–27]. The seroprevalence rates are also high in many countries of the South-Central and Western Asia - 78% in Jordan, 77% in Iran, 78% in Iraq, 75% in Saudi Arabia and 72% in Israel [15,28]. In addition, a temporal effect was also evident with the younger population having low prevalence rates similar to developed Western countries [2].

A temporal effect in *H. pylori* seroprevalence rate has also been noted in Asia [29,30]. In a study from Guangzhou province in China, it was found that the overall *H. pylori* seroprevalence rate had decreased from 62.5% in 1993 to 47% in 2003. Among children aged 1–5 years, the seroprevalence rate was 19.4% and this rose to 63.2% among subjects aged 40–50 years. In Japan, the overall seroprevalence rate was 72.7% in 1974, decreased to 54.6% in 1984 and was 39.3% in 1994. In South Korea, the seroprevalence rate decreased from 66.9% in 1998 to 59.6% in 2005 [31]. In addition to a temporal decline in the overall seroprevalence rate over time, the younger population generally has a lower seroprevalence rate. Current evidence suggests that most *H. pylori* infection is acquired in childhood. The data from Asia also indicates that the rate of *H. pylori* infection has been decreasing over the last 40–50 years, with an overall decline in *H. pylori* seroprevalence, similar to that of Western developed countries [2,32–34]. Evidence related to the survival of *H. pylori* outside the gastric niche is limited. Principal route of transmission yet to be confirmed. There is strong evidence that indicates the prevalence of *H. pylori* infection has a strong correlation with access to clean water, suggesting a transmission route to the host [35,36].

The Indian enigma is a subset of the Asian enigma, which refers to the observations that there are regions where *H. pylori* infection is high yet the GC incidence is relatively low. The term was coined based on the epidemiological observation. The regions where these observations are made are India, Bangladesh, Pakistan and Thailand [2,4,5]. It is to be acknowledged that there are still gaps in our appreciation of the process of gastric carcinogenesis. There is also a lack of data documenting the precise gastric histology in these populations with low g GC but high *H. pylori* seroprevalence rates [37,38].

**MOLECULAR EPIDEMIOLOGY OF *H. PYLORI* IN ASIA**

Different *H. pylori* strains transpire across diverse geographic regions, and the differences in these strains have been correlated with the variation in GC epidemiology. Six main geographic strains were identified, the hpEastAsia is the strain from East Asian countries [39]. It has been perceived that populations with high GC rates correspond almost exactly to populations with the hpEastAsia strain. In South Asian countries where *H. pylori* seroprevalence rates are high but GC prevalence rates are low, the strains were predominantly hpAsia [29,39–41].

In the milieu of GC carcinogenesis, bacterial virulence factors that have been implicated include the cytotoxin-associated gene A antigen (Cag A), vacuolating cytotoxin (VacA), and outer membrane proteins (OMP) [41]. Huang *et al*[42] performed a meta-analysis of 16 studies with 2284 cases and 2770 controls to scrutinize the relationship between CagA seropositivity and the risk of GC and indicated that infection with cagA-positive strains of *H. pylori* amplified the risk for GC over the risk associated with *H. pylori* infection alone. CagA protein has been classified into Western and Eastern types. The East Asian strain has been documented to be more virulent than the Western CagA with respect to clinical outcomes [42,43]. Azuma *et al*[44] validated that in the grades of inflammation and mucosal atrophy were significantly higher in patients infected with Eastern CagA-positive strains than in those infected with Western CagA-positive strains. Satomi *et al*[45] revealed that in Okinawa, Japan, where both Western and East Asian CagA were present, the prevalence of East Asian CagA-positive strains was significantly higher in patients with GC (84.6%) than in patients with duodenal ulcer (27.3%). There are increased frequencies of GC in individuals with type O blood and in secretors [expressing Le (b) antigen], but other studies have not found any relationship between blood groups and this infection [46,47]. The prevalence of *H. pylori* infection in intestinal-type GC is higher than in the diffuse type and in the control group. An association was found between *H. pylori* infection and GC located distally (antrum/pylorus) [48].

**MANAGEMENT AND OUTCOME OF GC IN ASIA**

GC management has been principally focused on the management of advanced GC in western populations, where the risk of GC tends to fall into the low-risk category. But this statement does not hold true for the highest-risk continent – Asia, where resources have focused on preventive strategies as well as management of early stage GC [49]. It is widely accepted that GC, like many other malignancies, progresses through a cancer cascade [50]. However, why certain individuals and families have a greater propensity to move along the cascade towards GC, is most certainly a multi-factorial process, and arises from complex and multifaceted interactions between host factors, *H. pylori* and environmental factors. Diets high in salt and nitrates carry the highest risks, with salt in particular demonstrating an ability to augment the effects of carcinogens. Fresh fruits and vegetables are associated with a reduced risk of GC. But fortification of the diet with ascorbic acid or use of multivitamins does not appear to confer the same protection. Studies focusing on sustained measurable alterations in diet sufficient to affect GC incidence and prevalence are underway [51–53].

However, *H. pylori* infection has proven to be an interesting target and multiple studies have indicated that *H. pylori* infection is a necessary, but not a sufficient causal factor in the development of GC[51]. Unfortunately, four randomized placebo-controlled trials evaluating the impact of *H. pylori* screening and eradication on GC prevalence did not show a significant reduction in GC development; however, there was a non-significant trend towards risk reduction for GC with *H. pylori* eradication. The strategy of population screening and treatment of *H. pylori* infection appears to be the strategy of choice in high GC risk populations in Eastern Asia [54–57].

China, Japan and South Korea are the in champions in the management of early GC, and this has primarily been driven by need. Given that these countries have some of the highest GC, screening is done through barium meal (Japan), gastroscopy (Japan and South Korea) and serum pepsinogen/gastroscopy (China) [55–57]. Studies from the eastern Asia examining the techniques of endoscopic mucosal resection and endoscopic submucosal dissection for early stage GC have proven that with improving technical expertise and careful surveillance, the outcome is excellent with high 5-year survival [58]. However, the detection of early GC is difficult and only systematic population screening has been shown to increase early detection and confer a survival advantage [59,60]. Health economics modeling indicates that population endoscopic screening for early GC is cost effective in moderate- to high-risk populations and may not be economically prudent for other part of Asia [59,61].

In the management and outcome of advanced GC, the majority of the studies have been carried out in the Western world, as most of the cases of GC are diagnosed at advanced stages [62]. The backbone of the management of advanced GC is chemotherapy, which is comparable between Western world and Asia [63]. The S1-cisplatin doublet remains the standard chemotherapy regimen for advanced GC in Japan, replacing 5FU-cisplatin. S1-cisplatin is also available in South Korea, Singapore, Taiwan, Philippines and China for this indication, but is not approved in North America[64,65]. Fluoro-pyrimidines show less toxicity in Asian populations, possibly secondary to polymorphisms in genes encoding drug-metabolizing enzymes, translating into more options for advanced GC treatments in Asian populations. Better survival differences after gastrectomy for GC favoring Asians patients may be explained by different disease patterns, the related need for fewer extensive procedures, and fewer patient risk factors in Eastern Asia. In other parts of Asia, the outcomes after surgery are variable [9,58,66]. The overall 1 and 5–year survivals are comparable between Asia, Europe, and North America according to gender and stage. there are slight variations of outcomes among different regions of Asia, depending on socioeconomic condition and access to medical care [9,65,67].

**CONCLUSION**

GC is exerting a significant health and economic burden in many countries of Asia [3]. The gradual and consistent improvement in socioeconomic condition in Asia has brought about an overall decrease in *H. pylori* seroprevalence rates and thus improvement of GC incidence[2,7]. Nonetheless, differences in still exist between developed and less developed countries of Asia[7,68]. There is now better understanding of the process of gastric carcinogenesis, and the role of bacterial virulence factors interrelating with host immune factors. In order to address the high clinical burden of GC, a recent Asia-Pacific Gastric Cancer Consensus meeting has strongly recommended a strategy for *H. pylori* screening and eradication in high-risk populations to reduce GC incidence. On the other hand, there have been continuous efforts to improve the screening, early diagnosis, surgical and medical management and surveillance of GC [7].

Similar to the Western world, the incidence and prevalence of *H. pylori* infection and GC in Asia has decreased over the past few decades. Multiple factors have played interactive roles in this regard. With a better understanding of the molecular epidemiology of *H. pylori* infection, GC carcinogenesis and overall improved management of GC, the clinical outcome is slowly improving[69,70]. However, more elaborative and circumferential steps have to be taken for primary, secondary and tertiary prevention of GC in Asia which in turn will eventually decrease the global burden of GC.

**REFERENCES**

1 **Yang L**. Incidence and mortality of gastric cancer in China. *World J Gastroenterol* 2006; **12**: 17-20 [PMID: 16440411]

2 **Fock KM**, Ang TL. Epidemiology of Helicobacter pylori infection and gastric cancer in Asia. *J Gastroenterol Hepatol* 2010; **25**: 479-486 [PMID: 20370726]

3 **International Agency for Research on Cancer.** Available from: URL: http: //globocan.iarc.fr/. Accessed September 20, 2013

4 **World Health Organization.** Available from: URL: http: //www.who.int/en/. Accessed September 07, 2013

5 **Matsuda A**, Matsuda T, Shibata A, Katanoda K, Sobue T, Nishimoto H. Cancer incidence and incidence rates in Japan in 2007: a study of 21 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project. *Jpn J Clin Oncol* 2013; **43**: 328-336 [PMID: 23296772 DOI: 10.1093/jjco/hys233]

6 **Kim JY**, Lee HS, Kim N, Shin CM, Lee SH, Park YS, Hwang JH, Kim JW, Jeong SH, Lee DH, Park do J, Kim HH, Jung HC. Prevalence and clinicopathologic characteristics of gastric cardia cancer in South Korea. *Helicobacter* 2012; **17**: 358-368 [PMID: 22967119]

7 **Goh KL**. Changing trends in gastrointestinal disease in the Asia-Pacific region. *J Dig Dis* 2007; **8**: 179-185 [PMID: 17970873]

8 **Guo P**, Huang ZL, Yu P, Li K. Trends in cancer mortality in China: an update. *Ann Oncol* 2012; **23**: 2755-2762 [PMID: 22492700 DOI: 10.1093/annonc/mds069]

9 [**Zhou HJ**](http://www.ncbi.nlm.nih.gov/pubmed?term=Zhou%20HJ%5BAuthor%5D&cauthor=true&cauthor_uid=23194009)**,** [So JB](http://www.ncbi.nlm.nih.gov/pubmed?term=So%20JB%5BAuthor%5D&cauthor=true&cauthor_uid=23194009), [Yong WP](http://www.ncbi.nlm.nih.gov/pubmed?term=Yong%20WP%5BAuthor%5D&cauthor=true&cauthor_uid=23194009), [Luo N](http://www.ncbi.nlm.nih.gov/pubmed?term=Luo%20N%5BAuthor%5D&cauthor=true&cauthor_uid=23194009), [Zhu F](http://www.ncbi.nlm.nih.gov/pubmed?term=Zhu%20F%5BAuthor%5D&cauthor=true&cauthor_uid=23194009), [Naidoo N](http://www.ncbi.nlm.nih.gov/pubmed?term=Naidoo%20N%5BAuthor%5D&cauthor=true&cauthor_uid=23194009), [Li SC](http://www.ncbi.nlm.nih.gov/pubmed?term=Li%20SC%5BAuthor%5D&cauthor=true&cauthor_uid=23194009), [Yeoh KG](http://www.ncbi.nlm.nih.gov/pubmed?term=Yeoh%20KG%5BAuthor%5D&cauthor=true&cauthor_uid=23194009). Validation of the functional assessment of cancer therapy-gastric module for the Chinese population. *Health Qual Life Outcomes* 2012; **10:** 145 [PMID: 23194009 DOI: 10.1186/1477-7525-10-145]

10 **Matsuzaka M**, Fukuda S, Takahashi I, Shimaya S, Oyama T, Yaegaki M, Shimoyama T, Sakamoto J, Nakaji S, Umeda T. The decreasing burden of gastric cancer in Japan. *Tohoku J Exp Med* 2007; **212**: 207-219 [PMID: 17592208 DOI: 10.1620/tjem.212.207]

11 **Asaka M.** A new approach for elimination of gastric cancer deaths in Japan. *Int J Cancer* 2013; **132:** 1272–6 [PMID: 23180638 DOI: 10.1002/ijc.27965]

12 [**Choi KS**](http://www.ncbi.nlm.nih.gov/pubmed?term=Choi%20KS%5BAuthor%5D&cauthor=true&cauthor_uid=23209638)**,**[Jun JK](http://www.ncbi.nlm.nih.gov/pubmed?term=Jun%20JK%5BAuthor%5D&cauthor=true&cauthor_uid=23209638), [Park EC](http://www.ncbi.nlm.nih.gov/pubmed?term=Park%20EC%5BAuthor%5D&cauthor=true&cauthor_uid=23209638), [Park S](http://www.ncbi.nlm.nih.gov/pubmed?term=Park%20S%5BAuthor%5D&cauthor=true&cauthor_uid=23209638), [Jung KW](http://www.ncbi.nlm.nih.gov/pubmed?term=Jung%20KW%5BAuthor%5D&cauthor=true&cauthor_uid=23209638), [Han MA](http://www.ncbi.nlm.nih.gov/pubmed?term=Han%20MA%5BAuthor%5D&cauthor=true&cauthor_uid=23209638), [Choi IJ](http://www.ncbi.nlm.nih.gov/pubmed?term=Choi%20IJ%5BAuthor%5D&cauthor=true&cauthor_uid=23209638), [Lee HY](http://www.ncbi.nlm.nih.gov/pubmed?term=Lee%20HY%5BAuthor%5D&cauthor=true&cauthor_uid=23209638). Performance of different gastric cancer screening methods in Korea: a population-based study. *PLoS One* 2012; **7:** e50041 [PMID: 23209638 DOI: 10.1371/journal.pone.0050041]

13 **Matsuhisa T,** Aftab H. Observation of gastric mucosa in Bangladesh, the country with the lowest incidence of gastric cancer, and Japan, the country with the highest incidence. *Helicobacter* 2012; **17:** 396–401 [PMID: 22967124]

14 **Dikshit RP,** Mathur G, Mhatre S, Yeole BB. Epidemiological review of gastric cancer in India. *Indian J Med Paediatr Oncol* 2011; **32:** 3–11 [PMID: 21731209 DOI: 10.4103/0971-5851.81883]

15 **Hussein NR.** Helicobacter pylori and gastric cancer in the Middle East: a new enigma? *World J Gastroenterol* 2010; **16:** 3226–34 [PMID: 20614477]

16 **Malekzadeh R**, Derakhshan MH, Malekzadeh Z. Gastric cancer in Iran: epidemiology and risk factors. *Arch Iran Med* 2009; **12**: 576-583 [PMID: 19877751]

17 **Haidari M**, Nikbakht MR, Pasdar Y, Najaf F. Trend analysis of gastric cancer incidence in Iran and its six geographical areas during 2000-2005. *Asian Pac J Cancer Prev* 2012; **13**: 3335-3341 [PMID: 22994757 DOI: 10.7314/APJCP.2012.13.7.3335]

18 **Goh KL**, Parasakthi N. The racial cohort phenomenon: seroepidemiology of Helicobacter pylori infection in a multiracial South-East Asian country. *Eur J Gastroenterol Hepatol* 2001; **13**: 177-183 [PMID: 11246618]

19 **Ahmad MM**, Rahman M, Rumi AK, Islam S, Huq F, Chowdhury MF, Jinnah F, Morshed MG, Hassan MS, Khan AK, Hasan M. Prevalence of Helicobacter pylori in asymptomatic population--a pilot serological study in Bangladesh. *J Epidemiol* 1997; **7**: 251-254 [PMID: 9465552 DOI: 10.2188/jea.7.251]

20 **Graham DY**, Adam E, Reddy GT, Agarwal JP, Agarwal R, Evans DJ, Malaty HM, Evans DG. Seroepidemiology of Helicobacter pylori infection in India. Comparison of developing and developed countries. *Dig Dis Sci* 1991; **36**: 1084-1088 [PMID: 1864201]

21 **Wang KJ**, Wang RT. [Meta-analysis on the epidemiology of Helicobacter pylori infection in China]. *Zhonghua Liu Xing Bing Xue Za Zhi* 2003; **24**: 443-446 [PMID: 12848905]

22 **Fujisawa T**, Kumagai T, Akamatsu T, Kiyosawa K, Matsunaga Y. Changes in seroepidemiological pattern of Helicobacter pylori and hepatitis A virus over the last 20 years in Japan. *Am J Gastroenterol* 1999; **94**: 2094-2099 [PMID: 10445533]

23 **Yim JY**, Kim N, Choi SH, Kim YS, Cho KR, Kim SS, Seo GS, Kim HU, Baik GH, Sin CS, Cho SH, Oh BH. Seroprevalence of Helicobacter pylori in South Korea. *Helicobacter* 2007; **12**: 333-340 [PMID: 17669107 DOI: 10.1111/j.1523-5378.2007.00504.x]

24 **Teh BH**, Lin JT, Pan WH, Lin SH, Wang LY, Lee TK, Chen CJ. Seroprevalence and associated risk factors of Helicobacter pylori infection in Taiwan. *Anticancer Res* 1994; **14**: 1389-1392 [PMID: 8067711]

25 **Fock KM**. Helicobacter pylori infection--current status in Singapore. *Ann Acad Med Singapore* 1997; **26**: 637-641 [PMID: 9494671]

26 **Deankanob W**, Chomvarin C, Hahnvajanawong C, Intapan PM, Wongwajana S, Mairiang P, Kularbkaew C, Sangchan A. Enzyme-linked immunosorbent assay for serodiagnosis of Helicobacter pylori in dyspeptic patients and volunteer blood donors. *Southeast Asian J Trop Med Public Health* 2006; **37**: 958-965 [PMID: 17333740]

27 **Hoang TTH,** Bengtsson C, Phung DC, Sörberg M, Granström M. Seroprevalence of Helicobacter pylori infection in urban and rural Vietnam. *Clin Diagn Lab Immunol* 2005; **12:** 81–5 [PMID: 15642989]

28 **Novis BH,** Gabay G, Naftali T. Helicobacter pylori: the Middle East scenario. *Yale J Biol Med* 1998; **71:** 135–41 [PMID: 10378359 DOI: 10.1128/CDLI.12.1.81-85.2005]

29 **Falush D**, Wirth T, Linz B, Pritchard JK, Stephens M, Kidd M, Blaser MJ, Graham DY, Vacher S, Perez-Perez GI, Yamaoka Y, Mégraud F, Otto K, Reichard U, Katzowitsch E, Wang X, Achtman M, Suerbaum S. Traces of human migrations in Helicobacter pylori populations. *Science* 2003; **299**: 1582-1585 [PMID: 12624269]

30 [**Moodley Y**](http://www.ncbi.nlm.nih.gov/pubmed?term=Moodley%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=19164753)**,** [Linz B](http://www.ncbi.nlm.nih.gov/pubmed?term=Linz%20B%5BAuthor%5D&cauthor=true&cauthor_uid=19164753), [Yamaoka Y](http://www.ncbi.nlm.nih.gov/pubmed?term=Yamaoka%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=19164753), [Windsor HM](http://www.ncbi.nlm.nih.gov/pubmed?term=Windsor%20HM%5BAuthor%5D&cauthor=true&cauthor_uid=19164753), [Breurec S](http://www.ncbi.nlm.nih.gov/pubmed?term=Breurec%20S%5BAuthor%5D&cauthor=true&cauthor_uid=19164753), [Wu JY](http://www.ncbi.nlm.nih.gov/pubmed?term=Wu%20JY%5BAuthor%5D&cauthor=true&cauthor_uid=19164753), [Maady A](http://www.ncbi.nlm.nih.gov/pubmed?term=Maady%20A%5BAuthor%5D&cauthor=true&cauthor_uid=19164753), [Bernhöft S](http://www.ncbi.nlm.nih.gov/pubmed?term=Bernh%C3%B6ft%20S%5BAuthor%5D&cauthor=true&cauthor_uid=19164753), [Thiberge JM](http://www.ncbi.nlm.nih.gov/pubmed?term=Thiberge%20JM%5BAuthor%5D&cauthor=true&cauthor_uid=19164753), [Phuanukoonnon S](http://www.ncbi.nlm.nih.gov/pubmed?term=Phuanukoonnon%20S%5BAuthor%5D&cauthor=true&cauthor_uid=19164753), [Jobb G](http://www.ncbi.nlm.nih.gov/pubmed?term=Jobb%20G%5BAuthor%5D&cauthor=true&cauthor_uid=19164753), [Siba P](http://www.ncbi.nlm.nih.gov/pubmed?term=Siba%20P%5BAuthor%5D&cauthor=true&cauthor_uid=19164753), [Graham DY](http://www.ncbi.nlm.nih.gov/pubmed?term=Graham%20DY%5BAuthor%5D&cauthor=true&cauthor_uid=19164753), [Marshall BJ](http://www.ncbi.nlm.nih.gov/pubmed?term=Marshall%20BJ%5BAuthor%5D&cauthor=true&cauthor_uid=19164753),[Achtman M](http://www.ncbi.nlm.nih.gov/pubmed?term=Achtman%20M%5BAuthor%5D&cauthor=true&cauthor_uid=19164753). The peopling of the Pacific from a bacterial perspective. *Science* 2009; **323:** 527–30 [PMID: 19164753 DOI: 10.1126/science.1166083]

31 **Chen J**, Bu XL, Wang QY, Hu PJ, Chen MH. Decreasing seroprevalence of Helicobacter pylori infection during 1993-2003 in Guangzhou, southern China. *Helicobacter* 2007; **12**: 164-169 [PMID: 17309754 DOI: 10.1111/j.1523-5378.2007.00487.x]

32 **Fock KM,** Dhamodaran S TE. Is H. pylori genotypes significant in Asian patients with gastric cancer and GERD? *Gut* 2006; **55**: A258

33 **Jais M**, Barua S. Seroprevalence of anti Helicobacter pylori IgG/IgA in asymptomatic population from Delhi. *J Commun Dis* 2004; **36**: 132-135 [PMID: 16295676]

34 **Perez-Perez GI**, Taylor DN, Bodhidatta L, Wongsrichanalai J, Baze WB, Dunn BE, Echeverria PD, Blaser MJ. Seroprevalence of Helicobacter pylori infections in Thailand. *J Infect Dis* 1990; **161**: 1237-1241 [PMID: 2345304 DOI: 10.1093/infdis/161.6.1237]

35 **Percival SL**, Thomas JG. Transmission of Helicobacter pylori and the role of water and biofilms. *J Water Health* 2009; **7**: 469-477 [PMID: 19491497 DOI: 10.2166/wh.2009.070]

36 **Calvet X**, Ramírez Lázaro MJ, Lehours P, Mégraud F. Diagnosis and epidemiology of Helicobacter pylori infection. *Helicobacter* 2013; **18 Suppl 1**: 5-11 [PMID: 24011238]

37 **Graham DY,** Lu H, Yamaoka Y. African, Asian or Indian enigma, the East Asian Helicobacter pylori: facts or medical myths. *J Dig Dis* 2009; **10:** 77–84 [PMID: 19426388]

38 **Ang TL**, Fock KM, Dhamodaran S, Teo EK, Tan J. Racial differences in Helicobacter pylori, serum pepsinogen and gastric cancer incidence in an urban Asian population. *J Gastroenterol Hepatol* 2005; **20**: 1603-1609 [PMID: 16174081 DOI: 10.1111/j.1440-1746.2005.03898.x]

39 **Yamaoka Y,** Kato M, Asaka M. Geographic differences in gastric cancer incidence can be explained by differences between Helicobacter pylori strains. *Intern Med* 2008; **47:** 1077–83 [PMID: 18552463]

40 **Linz B,** Balloux F, Moodley Y. An African origin for the intimate association between humans and Helicobacter pylori. *Nature* 2007; **445:** 915–8 [PMID: 17287725 DOI: 10.1038/nature05562]

41 **McNamara D**, El-Omar E. Helicobacter pylori infection and the pathogenesis of gastric cancer: a paradigm for host-bacterial interactions. *Dig Liver Dis* 2008; **40**: 504-509 [PMID: 18486572 DOI: 10.1016/j.dld.2008.02.031]

42 **Huang JQ**, Zheng GF, Sumanac K, Irvine EJ, Hunt RH. Meta-analysis of the relationship between cagA seropositivity and gastric cancer. *Gastroenterology* 2003; **125**: 1636-1644 [PMID: 14724815 DOI: 10.1053/j.gastro.2003.08.033]

43 **Nguyen LT**, Uchida T, Murakami K, Fujioka T, Moriyama M. Helicobacter pylori virulence and the diversity of gastric cancer in Asia. *J Med Microbiol* 2008; **57**: 1445-1453 [PMID: 19018013 DOI: 10.1099/jmm.0.2008/003160-0]

44 [**Azuma T**](http://www.ncbi.nlm.nih.gov/pubmed?term=Azuma%20T%5BAuthor%5D&cauthor=true&cauthor_uid=15184428)**,**[Yamakawa A](http://www.ncbi.nlm.nih.gov/pubmed?term=Yamakawa%20A%5BAuthor%5D&cauthor=true&cauthor_uid=15184428), [Yamazaki S](http://www.ncbi.nlm.nih.gov/pubmed?term=Yamazaki%20S%5BAuthor%5D&cauthor=true&cauthor_uid=15184428), [Ohtani M](http://www.ncbi.nlm.nih.gov/pubmed?term=Ohtani%20M%5BAuthor%5D&cauthor=true&cauthor_uid=15184428), [Ito Y](http://www.ncbi.nlm.nih.gov/pubmed?term=Ito%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=15184428), [Muramatsu A](http://www.ncbi.nlm.nih.gov/pubmed?term=Muramatsu%20A%5BAuthor%5D&cauthor=true&cauthor_uid=15184428), [Suto H](http://www.ncbi.nlm.nih.gov/pubmed?term=Suto%20H%5BAuthor%5D&cauthor=true&cauthor_uid=15184428), [Yamazaki Y](http://www.ncbi.nlm.nih.gov/pubmed?term=Yamazaki%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=15184428), [Keida Y](http://www.ncbi.nlm.nih.gov/pubmed?term=Keida%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=15184428), [Higashi H](http://www.ncbi.nlm.nih.gov/pubmed?term=Higashi%20H%5BAuthor%5D&cauthor=true&cauthor_uid=15184428), [Hatakeyama M](http://www.ncbi.nlm.nih.gov/pubmed?term=Hatakeyama%20M%5BAuthor%5D&cauthor=true&cauthor_uid=15184428). Distinct diversity of the cag pathogenicity island among Helicobacter pylori strains in Japan. *J Clin Microbiol* 2004; **42:** 2508–17 [PMID: 15184428 DOI: 10.1128/JCM.42.6.2508-2517.2004]

45 **Satomi S**, Yamakawa A, Matsunaga S, Masaki R, Inagaki T, Okuda T, Suto H, Ito Y, Yamazaki Y, Kuriyama M, Keida Y, Kutsumi H, Azuma T. Relationship between the diversity of the cagA gene of Helicobacter pylori and gastric cancer in Okinawa, Japan. *J Gastroenterol* 2006; **41**: 668-673 [PMID: 16933004 DOI: 10.1007/s00535-006-1838-6]

46 **Keramati MR,** Sadeghian MH, Ayatollahi H, Badiee Z, Shakibayi H, Moghimi-Roudi A. Role of the Lewis and ABO Blood Group Antigens in Helicobacter pylori Infection. *Malays J Med Sci* 2012; **19:** 17–21 [PMID: 23610545]

47 **Aryana K,** Keramati MR, Zakavi SR, Sadeghian MH, Akbari H. Association of Helicobacter pylori infection with the Lewis and ABO blood groups in dyspeptic patients. *Niger Med J* 2013; **54:** 196–9 [PMID: 23901182]

48 **Martín-de-Argila C**, Boixeda D, Redondo C, Alvarez I, Gisbert JP, García Plaza A, Cantón R. Relation between histologic subtypes and location of gastric cancer and Helicobacter pylori. *Scand J Gastroenterol* 1997; **32**: 303-307 [PMID: 9140150]

49 **Parkin DM**, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. *CA Cancer J Clin* ; **55**: 74-108 [PMID: 15761078 DOI: 10.3322/canjclin.55.2.74]

50 **Correa P**, Piazuelo MB, Camargo MC. The future of gastric cancer prevention. *Gastric Cancer* 2004; **7**: 9-16 [PMID: 15052434 DOI: 10.1007/s10120-003-0265-0]

51 **Fock KM**, Katelaris P, Sugano K, Ang TL, Hunt R, Talley NJ, Lam SK, Xiao SD, Tan HJ, Wu CY, Jung HC, Hoang BH, Kachintorn U, Goh KL, Chiba T, Rani AA. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. *J Gastroenterol Hepatol* 2009; **24**: 1587-1600 [PMID: 19788600]

52 **Goh KL**, Cheah PL, Md N, Quek KF, Parasakthi N. Ethnicity and H. pylori as risk factors for gastric cancer in Malaysia: A prospective case control study. *Am J Gastroenterol* 2007; **102**: 40-45 [PMID: 17100981]

53 **Tatematsu M**, Takahashi M, Fukushima S, Hananouchi M, Shirai T. Effects in rats of sodium chloride on experimental gastric cancers induced by N-methyl-N-nitro-N-nitrosoguanidine or 4-nitroquinoline-1-oxide. *J Natl Cancer Inst* 1975; **55**: 101-106 [PMID: 808633 DOI: 10.1111/j.1572-0241.2006.00885.x]

54 **Wong BC**, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, Lai KC, Hu WH, Yuen ST, Leung SY, Fong DY, Ho J, Ching CK, Chen JS. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. *JAMA* 2004; **291**: 187-194 [PMID: 14722144 DOI: 10.1001/jama.291.2.187]

55 **Kim YS,** Park HA, Kim BS, Yook JH, Lee MS. Efficacy of screening for gastric cancer in a Korean adult population: a case-control study. *J Korean Med Sci* 2000; **15:** 510–5 [PMID: 11068986]

56 **Tsubono Y**, Hisamichi S. Screening for gastric cancer in Japan. *Gastric Cancer* 2000; **3**: 9-18 [PMID: 11984703]

57 **Liu CY**, Wu CY, Lin JT, Lee YC, Yen AM, Chen TH. Multistate and multifactorial progression of gastric cancer: results from community-based mass screening for gastric cancer. *J Med Screen* 2006; **13 Suppl 1**: S2-S5 [PMID: 17227633]

58 **Yamaguchi N**, Isomoto H, Fukuda E, Ikeda K, Nishiyama H, Akiyama M, Ozawa E, Ohnita K, Hayashi T, Nakao K, Kohno S, Shikuwa S. Clinical outcomes of endoscopic submucosal dissection for early gastric cancer by indication criteria. *Digestion* 2009; **80**: 173-181 [PMID: 19776581 DOI: 10.1159/000215388]

59 **Whiting JL,** Sigurdsson A, Rowlands DC, Hallissey MT, Fielding JWL. The long term results of endoscopic surveillance of premalignant gastric lesions. *Gut* 2002; **50:** 378–81[PMID: 11839718 DOI: 10.1136/gut.50.3.378]

60 **Kubota H**, Kotoh T, Masunaga R, Dhar DK, Shibakita M, Tachibana M, Kohno H, Nagasue N. Impact of screening survey of gastric cancer on clinicopathological features and survival: retrospective study at a single institution. *Surgery* 2000; **128**: 41-47 [PMID: 10876184 DOI: 10.1067/msy.2000.106812]

61 **Dan YY**, So JB, Yeoh KG. Endoscopic screening for gastric cancer. *Clin Gastroenterol Hepatol* 2006; **4**: 709-716 [PMID: 16765306 DOI: 10.1016/j.cgh.2006.03.025]

62 **Wagner AD**, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J, Fleig WE. Chemotherapy for advanced gastric cancer. *Cochrane Database Syst Rev* 2010; (3):CD004064 CD004064 [PMID: 20238327]

63 **Bang YJ**, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. *Lancet* 2010; **376**: 687-697 [PMID: 20728210 DOI: 10.1016/S0140-6736(10)61121-X]

64 **Koizumi W**, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. *Lancet Oncol* 2008; **9**: 215-221 [PMID: 18282805 DOI: 10.1016/S1470-2045(08)70035-4]

65 **Kim R**, Tan A, Choi M, El-Rayes BF. Geographic differences in approach to advanced gastric cancer: Is there a standard approach? *Crit Rev Oncol Hematol* 2013; **88**: 416-426 [PMID: 23764501 DOI: 10.1016/j.critrevonc.2013.05.007]

66 **Schwarz RE**, Zagala-Nevarez K. Ethnic survival differences after gastrectomy for gastric cancer are better explained by factors specific for disease location and individual patient comorbidity. *Eur J Surg Oncol* 2002; **28**: 214-219 [PMID: 11944952 DOI: 10.1053/ejso.2001.1234]

67 **Ma BB**, Hui EP, Mok TS. Population-based differences in treatment outcome following anticancer drug therapies. *Lancet Oncol* 2010; **11**: 75-84 [PMID: 20129130 DOI: 10.1016/S1470-2045(09)70160-3]

68 **Hu Y**, Fang JY, Xiao SD. Can the incidence of gastric cancer be reduced in the new century? *J Dig Dis* 2013; **14**: 11-15 [PMID: 23134264 DOI: 10.1111/j.1751-2980.2012.00647.x]

69 **Tural D,** Selçukbiricik F, Serdengeçti S, Büyükünal E. A comparison of patient characteristics, prognosis, treatment modalities, and survival according to age group in gastric cancer patients. *World J Surg Oncol* 2012; **10:** 234 [PMID: 23121731 DOI: 10.1186/1477-7819-10-234]

70 **Kato M**, Asaka M. Recent development of gastric cancer prevention. *Jpn J Clin Oncol* 2012; **42**: 987-994 [PMID: 23018579 DOI: 10.1093/jjco/hys151]

**P-Reviewers:** Deans C, Dalamaga M, Goral V **S-Editor:** Song XX **L-Editor:** **E-Editor:**

**Table 1 Gastric cancer incidence, mortality and prevalence in the world as reported in GLOBOCAN 2008 [**3**]**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **Total Incidence****(in 1000s)** | **Incidence rate****per 100000** | **Total Mortality****(in 1000s)** | **Mortality rate****per 100000** | **5-year prevalence****(in 1000s)** | **Prevalence**  |
| **World** | 988 | 14.0 | 737 | 10.3 | 1598 | 5.5**%** |
| **Asia** | 727 | 18.5 | 530 | 13.4 | 1216 | 10.4**%** |
| **Europe** | 145 | 10.3 | 116 | 7.9 | 201 | 2.4**%** |
| **N. America** | 24 | 4.2 | 12 | 2.1 | 37 | 0.8**%** |
| **Africa** | 22 | 4 | 21 | 3.8 | 30 | 2.1**%** |

**Table 2 Male gastric cancer incidence, mortality and prevalence in the world as reported in GLOBOCAN 2008 [**3**]**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **Total Incidence****(in 1000s)** | **Incidence rate****per 100000** | **Total Mortality****(in 1000s)** | **Mortality rate****per 100000** | **5-year prevalence****(in 1000s)** | **Prevalence** |
| **World** | 640 | 19.7 | 463 | 14.2 | 1050 | 7.8**%** |
| **Asia** | 484 | 25.9 | 342 | 18.3 | 819 | 15.7**%** |
| **Europe** | 86 | 14.5 | 68 | 11.3 | 121 | 2.9**%** |
| **N. America** | 15 | 5.8 | 7 | 2.8 | 23 | 1**%** |
| **Africa** | 12 | 4.7 | 11 | 4.5 | 16 | 3**%** |

**Table 3 Female gastric cancer incidence, mortality and prevalence in the world as reported in GLOBOCAN 2008 [**3**]**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **Total Incidence****(in 1000s)** | **Incidence rate****per 100000** | **Total Mortality****(in 1000s)** | **Mortality rate****per 100000** | **5-year prevalence****(in 1000s)** | **Prevalence** |
| World | 348 | 9.1 | 273 | 6.9 | 548 | 3.6**%** |
| Asia | 243 | 11.7 | 188 | 8.9 | 396 | 6.2**%** |
| Europe | 59 | 7 | 47 | 5.3 | 79 | 1.9**%** |
| N. America | 9 | 2.8 | 5 | 1.5 | 13 | 0.6**%** |
| Africa | 10 | 3.3 | 9 | 3.2 | 13 | 1.5**%** |

**Table 4 Gastric cancer incidence, mortality and prevalence in Asia as reported in GLOBOCAN 2008 [**3**]**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **Total Incidence****(in 1000s)** | **Incidence rate****per 100000** | **Total Mortality****(in 1000s)** | **Mortality rate****per 100000** | **5-year prevalence****(in 1000s)** | **Prevalence**  |
| **Eastern Asia** | 601 | 30.2 | 418 | 20.3 | 1071 | 15.2**%** |
| **South-Eastern Asia** | 43 | 8.6 | 35 | 7.1 | 56 | 3.9**%** |
| **South-Central Asia** | 68 | 4.8 | 63 | 6.5 | 68 | 2.6**%** |
| **Western Asia** | 14 | 9.4 | 13 | 8.3 | 19 | 4.2**%** |

**Table 5: Male gastric cancer incidence, mortality and prevalence in Asia as reported in GLOBOCAN 2008 [**3**]**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **Total Incidence****(in 1000s)** | **Incidence rate****per 100000** | **Total Mortality****(in 1000s)** | **Mortality rate****per 100000** | **5-year prevalence****(in 1000s)** | **Prevalence** |
| **Eastern Asia** | 408 | 42.4 | 274 | 28.1 | 732 | 21**%** |
| **South-Eastern Asia** | 24 | 10.9 | 20 | 8.9 | 32 | 6.2**%** |
| **South-Central Asia** | 42 | 6.7 | 39 | 6.3 | 42 | 4.3**%** |
| **Western Asia** | 9 | 12.6 | 8 | 11.2 | 12 | 5.8**%** |

**Table 6 Female gastric cancer incidence, mortality and prevalence in Asia as reported in GLOBOCAN 2008 [**3**]**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **Total Incidence (in 1000s)** | **Incidence rate****per 100000** | **Total Mortality (in 1000s)** | **Mortality rate****per 100000** | **5-year prevalence (in 1000s)** | **Prevalence** |
| **Eastern Asia** | 193 | 18.3 | 144 | 13 | 338 | 9.5**%** |
| **South-Eastern Asia** | 18 | 6.7 | 15 | 5.6 | 23 | 2.6**%** |
| **South-Central Asia** | 26 | 3.9 | 23 | 3.6 | 26 | 1.6**%** |
| **Western Asia** | 5 | 6.7 | 4 | 5.9 | 7 | 3.0**%** |

**Table 7 Incidence, mortality and prevalence of gastric cancer in selected countries in Asia as reported in GLOBOCAN 2008 [**3**]**

|  |  |  |  |
| --- | --- | --- | --- |
| **Country** | **Incidence rate per 100000** | **Mortality rate per 100000** | **Prevalence** |
| **China** | 29.9 | 22.3 | 5.6**%** |
| **Japan** | 31.1 | 13.5 | 18.1**%** |
| **South Korea** | 12.1 | 9.8 | 7.0**%** |
| **Indonesia** | 9.4 | 8.8 | 4.8**%** |
| **Malaysia** | 8.4 | 7.4 | 3.3**%** |
| **Thailand** | 3.5 | 2.5 | 1.5**%** |
| **India** | 3.8 | 3.6 | 1.5**%** |
| **Bangladesh** | 5.2 | 5.0 | 2.8**%** |
| **Pakistan** | 6.3 | 5.9 | 3.0**%** |
| **Iran** | 15.6 | 14.1 | 8.8**%** |
| **Iraq** | 3.6 | 3.5 | 1.9**%** |
| **Jordan** | 4.8 | 4.5 | 2.2**%** |
| **Saudi Arabia** | 3.3 | 3.0 | 2.0**%** |
| **Israel** | 8.6 | 4.7 | 2.4**%** |